KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Accured Expenses: 2011-2025

Historic Change in Accured Expenses for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to -$103.2 million.

  • Sarepta Therapeutics' Change in Accured Expenses fell 6223.03% to -$103.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.1 million, marking a year-over-year decrease of 144.47%. This contributed to the annual value of $110.6 million for FY2024, which is 320.70% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Change in Accured Expenses stood at -$103.2 million for Q3 2025, which was down 321.68% from -$24.5 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Change in Accured Expenses peaked at $124.2 million during Q4 2024, and registered a low of -$103.2 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$17.7 million (2025), whereas its average is -$7.7 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Change in Accured Expenses soared by 396.97% in 2024, and later tumbled by 6,223.03% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Change in Accured Expenses stood at $69.8 million in 2021, then slumped by 81.55% to $12.9 million in 2022, then surged by 374.36% to $61.1 million in 2023, then skyrocketed by 103.34% to $124.2 million in 2024, then slumped by 6,223.03% to -$103.2 million in 2025.
  • Its Change in Accured Expenses stands at -$103.2 million for Q3 2025, versus -$24.5 million for Q2 2025 and -$17.7 million for Q1 2025.